TR200102735T2 - Aşı. - Google Patents
Aşı.Info
- Publication number
- TR200102735T2 TR200102735T2 TR2001/02735T TR200102735T TR200102735T2 TR 200102735 T2 TR200102735 T2 TR 200102735T2 TR 2001/02735 T TR2001/02735 T TR 2001/02735T TR 200102735 T TR200102735 T TR 200102735T TR 200102735 T2 TR200102735 T2 TR 200102735T2
- Authority
- TR
- Turkey
- Prior art keywords
- relates
- antigen
- vaccine
- pneumococcal polysaccharide
- pneumococcal
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 150000004676 glycans Chemical class 0.000 abstract 3
- 229920001282 polysaccharide Polymers 0.000 abstract 3
- 239000005017 polysaccharide Substances 0.000 abstract 3
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Bu bulus bakteryel polisakarid antijen asilarla ilgilidir. Bu bulus özellikle, bir pnömokok kökenli polisakarid antijen, tipik olarak, Streptococcus pneumoniae' den elde edilen bir protein antijeni ile formüle edilen bir pnömokok kökenli polisakarid konjügat antijen ve istege bagli olarak bir Th-1-uyarici adjuvant içeren asilarla ilgilidir.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9906437.0A GB9906437D0 (en) | 1999-03-19 | 1999-03-19 | Vaccine |
GBGB9909077.1A GB9909077D0 (en) | 1999-04-20 | 1999-04-20 | Novel compositions |
GBGB9909466.6A GB9909466D0 (en) | 1999-04-23 | 1999-04-23 | Vaccines |
GBGB9916677.9A GB9916677D0 (en) | 1999-07-15 | 1999-07-15 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200102735T2 true TR200102735T2 (tr) | 2002-04-22 |
Family
ID=27451884
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/02736T TR200102736T2 (tr) | 1999-03-19 | 2000-03-17 | Aşı. |
TR2001/02739T TR200102739T2 (tr) | 1999-03-19 | 2000-03-17 | Aşı |
TR2001/02735T TR200102735T2 (tr) | 1999-03-19 | 2000-03-17 | Aşı. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/02736T TR200102736T2 (tr) | 1999-03-19 | 2000-03-17 | Aşı. |
TR2001/02739T TR200102739T2 (tr) | 1999-03-19 | 2000-03-17 | Aşı |
Country Status (32)
Country | Link |
---|---|
US (8) | US20030147922A1 (tr) |
EP (6) | EP1776962A1 (tr) |
JP (4) | JP2002539273A (tr) |
KR (3) | KR100798212B1 (tr) |
CN (3) | CN100339130C (tr) |
AR (3) | AR022963A1 (tr) |
AT (3) | ATE387214T1 (tr) |
AU (3) | AU750788B2 (tr) |
BE (1) | BE1025464I2 (tr) |
BR (4) | BR0009166A (tr) |
CA (3) | CA2366152A1 (tr) |
CY (3) | CY1107561T1 (tr) |
CZ (3) | CZ301445B6 (tr) |
DE (4) | DE60032120T2 (tr) |
DK (2) | DK1162999T3 (tr) |
ES (3) | ES2339737T3 (tr) |
FR (1) | FR10C0008I2 (tr) |
HK (3) | HK1043728B (tr) |
HU (4) | HU228499B1 (tr) |
IL (5) | IL145044A0 (tr) |
LU (1) | LU91652I2 (tr) |
MX (1) | MXPA01009452A (tr) |
MY (2) | MY125387A (tr) |
NL (1) | NL300415I1 (tr) |
NO (4) | NO330532B1 (tr) |
NZ (3) | NZ513840A (tr) |
PL (3) | PL204890B1 (tr) |
PT (2) | PT1163000E (tr) |
SI (2) | SI1162999T1 (tr) |
TR (3) | TR200102736T2 (tr) |
TW (3) | TWI286938B (tr) |
WO (3) | WO2000056358A2 (tr) |
Families Citing this family (272)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
US7078042B2 (en) * | 1995-09-15 | 2006-07-18 | Uab Research Foundation | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
EP0909323B1 (en) | 1996-01-04 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Helicobacter pylori bacterioferritin |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
US20010016200A1 (en) * | 1998-04-23 | 2001-08-23 | Briles David E. | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US6797275B1 (en) * | 1998-12-04 | 2004-09-28 | The United States Of America As Represented By The Department Of Health And Human Services | Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine |
HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
AU1412702A (en) | 2000-10-27 | 2002-05-06 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a and b |
GB2370770B (en) * | 2001-01-03 | 2005-06-01 | Simon Connolly | Uses of Streptococcus Vaccines |
US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
PL226184B1 (pl) * | 2001-01-23 | 2017-06-30 | Aventis Pasteur | Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko |
EP2281573A3 (en) | 2001-02-23 | 2011-12-07 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0109297D0 (en) * | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
GB0115176D0 (en) † | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
EP2335724A1 (en) | 2001-12-12 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia trachomatis |
GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
WO2003070909A2 (en) | 2002-02-20 | 2003-08-28 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
RU2378008C2 (ru) * | 2002-05-14 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс С.Р.Л. | Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку |
DE60328481D1 (de) * | 2002-05-14 | 2009-09-03 | Novartis Vaccines & Diagnostic | Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält |
GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
SI1549338T1 (sl) | 2002-10-11 | 2011-04-29 | Novartis Vaccines & Diagnostic | Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi |
WO2004035618A2 (en) * | 2002-10-15 | 2004-04-29 | Intercell Ag | Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
AU2003278166B2 (en) | 2002-11-01 | 2009-01-29 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
US10919956B2 (en) | 2002-11-12 | 2021-02-16 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
EP1562982B1 (en) | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics S.r.l. | Unexpected surface proteins in neisseria meningitidis |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CA2502015A1 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5' cpg nucleic acids and methods of use |
WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
FR2850106B1 (fr) | 2003-01-17 | 2005-02-25 | Aventis Pasteur | Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5 |
CA2514328C (en) | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
US9296795B2 (en) * | 2003-03-07 | 2016-03-29 | Wyeth Holdings, Llc. | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
AU2004219910B2 (en) * | 2003-03-13 | 2010-06-17 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
WO2005020964A1 (en) | 2003-06-02 | 2005-03-10 | Chiron Corporation | Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP1961426B1 (en) | 2003-10-02 | 2011-04-27 | Novartis Vaccines and Diagnostics S.r.l. | Combined meningitis vaccines |
GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
SI1740217T1 (sl) | 2004-04-30 | 2011-10-28 | Novartis Ag | Konjugirano meningokokno cepljenje |
US7444197B2 (en) * | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
EP2612679A1 (en) | 2004-07-29 | 2013-07-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP2433647A3 (en) | 2005-01-27 | 2012-06-06 | Children's Hospital & Research Center at Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US8758764B2 (en) | 2005-02-18 | 2014-06-24 | Novartis Vaccines And Diagnostics Srl | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia coli |
CN101203529A (zh) | 2005-02-18 | 2008-06-18 | 诺华疫苗和诊断公司 | 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸 |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN113198012A (zh) | 2005-04-08 | 2021-08-03 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2006113528A2 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
CN103083657B (zh) * | 2005-06-27 | 2016-06-08 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
EP1931380A2 (en) | 2005-09-01 | 2008-06-18 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Multiple vaccination including serogroup c meningococcus |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
ES2514316T3 (es) | 2005-11-22 | 2014-10-28 | Novartis Vaccines And Diagnostics, Inc. | Partículas similares a virus (VLPs) de Norovirus y Sapovirus |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
AR058707A1 (es) | 2005-12-22 | 2008-02-20 | Glaxosmithkline Biolog Sa | Vacuna, procedimiento para fabricarla y su uso |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CA2636566C (en) * | 2006-01-17 | 2018-03-13 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein e; pe) |
CN101024079B (zh) * | 2006-02-17 | 2012-02-01 | 福州昌晖生物工程有限公司 | 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法 |
BRPI0708849B1 (pt) * | 2006-03-17 | 2022-05-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para a preparação de conjugados imunogênicos multivalentes complexos, os referidos conjugados, e composições farmacêuticas |
GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
TR201807355T4 (tr) | 2006-03-22 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Meningokokkal konjugatlarla immünizasyon rejimleri. |
US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
JO3418B1 (ar) * | 2006-03-30 | 2019-10-20 | Glaxosmithkline Biologicals Sa | عملية اقتران خاصة ب pnag وبروتين حامل |
BRPI0710210A2 (pt) * | 2006-03-30 | 2011-05-24 | Glaxomithkline Biolog S A | composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
EP2035035A2 (en) * | 2006-06-09 | 2009-03-18 | Novartis AG | Immunogenic compositions for streptococcus agalactiae |
GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
DK2074221T3 (da) * | 2006-10-10 | 2010-09-06 | Wyeth Llc | Forbedrede fremgangsmåder til separation af streptococcus pneumoniae type 3 polysakkarider |
GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
EP2167121B1 (en) | 2007-06-26 | 2015-09-02 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
RU2471497C2 (ru) | 2007-09-12 | 2013-01-10 | Новартис Аг | Мутантные антигены gas57 и антитела против gas57 |
BRPI0818545A2 (pt) | 2007-10-19 | 2017-07-04 | Novartis Ag | formulações de vacinais meningocócicas |
WO2009062132A2 (en) | 2007-11-09 | 2009-05-14 | California Institute Of Technology | Immunomodulating compounds and related compositions and methods |
AU2008335457B2 (en) | 2007-12-07 | 2015-04-16 | Glaxosmithkline Biologicals S.A. | Compositions for inducing immune responses |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
CN101977926B (zh) | 2007-12-21 | 2014-10-08 | 诺华股份有限公司 | 链球菌溶血素o的突变形式 |
EP2252326A4 (en) * | 2008-02-01 | 2012-08-29 | Newcastle Innovation Ltd | VACCINE COMPOSITIONS |
EP2886551A3 (en) | 2008-02-21 | 2015-09-23 | Novartis AG | Meningococcal fhbp polypeptides |
AU2009223613B2 (en) | 2008-03-10 | 2014-09-25 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
RU2532911C2 (ru) | 2008-07-21 | 2014-11-20 | Дзе Брихэм Энд Уимен'З Хоспитал, Инк. | Способы и композиции, относящиеся к синтетическим бета-1,6-глюкозаминолигосахаридам |
HUE029265T2 (en) | 2008-10-27 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Method of purifying carbohydrates from the group streptococci |
MX337723B (es) | 2008-12-09 | 2016-03-15 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige. |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
US8585505B2 (en) | 2008-12-15 | 2013-11-19 | Tetris Online, Inc. | Inter-game interactive hybrid asynchronous computer game infrastructure |
CN102300585A (zh) | 2008-12-17 | 2011-12-28 | 诺华有限公司 | 包含血红蛋白受体的脑膜炎球菌疫苗 |
EP2384120B1 (en) | 2009-01-05 | 2019-12-11 | Epitogenesis Inc. | Adjuvant compositions and methods of use |
WO2010079464A1 (en) | 2009-01-12 | 2010-07-15 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
AU2010227220B2 (en) | 2009-03-24 | 2014-11-13 | Glaxosmithkline Biologicals S.A. | Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates |
CN102427826B (zh) | 2009-03-24 | 2014-11-26 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
US8679505B2 (en) | 2009-04-14 | 2014-03-25 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
US8668911B2 (en) | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
CA2766418C (en) | 2009-06-22 | 2016-03-29 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
JP5395264B2 (ja) | 2009-06-22 | 2014-01-22 | ワイス・エルエルシー | 黄色ブドウ球菌(staphylococcusaureus)抗原の免疫原性組成物 |
US8647621B2 (en) | 2009-07-27 | 2014-02-11 | Fina Biosolutions, Llc | Method of producing protein-carbohydrate vaccines reduced in free carbohydrate |
MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
NZ598458A (en) | 2009-08-27 | 2014-03-28 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
NZ599059A (en) | 2009-09-03 | 2014-05-30 | Pfizer Vaccines Llc | Pcsk9 vaccine |
US20120237536A1 (en) | 2009-09-10 | 2012-09-20 | Novartis | Combination vaccines against respiratory tract diseases |
CN102917730A (zh) | 2009-10-27 | 2013-02-06 | 诺华有限公司 | 修饰的脑膜炎球菌fHBP多肽 |
EP3199177A1 (en) | 2009-10-30 | 2017-08-02 | GlaxoSmithKline Biologicals S.A. | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
MX2012006961A (es) | 2009-12-17 | 2012-10-03 | Fina Biosolutions Llc | Reactivos quimicos para la activacion de polisacaridos en la preparacion de vacunas conjugadas. |
AU2010334428B2 (en) | 2009-12-22 | 2015-05-21 | Celldex Therapeutics, Inc. | Vaccine compositions |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
ES2910199T3 (es) | 2010-03-30 | 2022-05-11 | Childrens Hospital & Res Center At Oakland | Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
JP6027961B2 (ja) | 2010-04-07 | 2016-11-16 | シェン, ユエSHEN, Yue | 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム |
WO2011146910A1 (en) * | 2010-05-20 | 2011-11-24 | Round June L | Antigen specific tregs and related compositions, methods and systems |
PL3170508T3 (pl) * | 2010-06-04 | 2020-04-30 | Wyeth Llc | Preparaty szczepionek |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
WO2011154863A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
WO2011161653A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
EP2655389A2 (en) | 2010-12-24 | 2013-10-30 | Novartis AG | Compounds |
WO2012103421A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Adjuvant nanoemulsions with crystallisation inhibitors |
CN103533954B (zh) | 2011-03-02 | 2015-09-09 | 诺华股份有限公司 | 含较低剂量的抗原和/或佐剂的联合疫苗 |
GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
EP2511295A1 (en) | 2011-04-15 | 2012-10-17 | Institut National De La Sante Et De La Recherche Medicale | Compositions for preventing and/or treating an infection by an HIV-1 virus |
EP2705853B1 (en) | 2011-05-06 | 2018-07-18 | Aparin, Petr Gennadievich | Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same |
WO2012178118A1 (en) | 2011-06-24 | 2012-12-27 | Epitogenesis Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
CN103764171B (zh) | 2011-07-08 | 2016-08-17 | 诺华股份有限公司 | 酪氨酸连接方法 |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
EP2755683B1 (en) | 2011-09-14 | 2019-04-03 | GlaxoSmithKline Biologicals SA | Methods for making saccharide-protein glycoconjugates |
WO2013043518A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
WO2013068949A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
DE102011122891B4 (de) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
DE102011118371B4 (de) | 2011-11-11 | 2014-02-13 | Novartis Ag | Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung |
EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
US9694063B2 (en) | 2011-12-08 | 2017-07-04 | Glaxosmithkline Biologicals Sa | Clostridium difficile toxin-based vaccine |
GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
JP2015505309A (ja) | 2011-12-29 | 2015-02-19 | ノバルティス アーゲー | 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ |
MX2014010011A (es) | 2012-02-24 | 2014-09-08 | Novartis Ag | Proteinas y composiciones de pilus. |
WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
JP2015509963A (ja) | 2012-03-08 | 2015-04-02 | ノバルティス アーゲー | Tlr4アゴニストを含む混合ワクチン |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
WO2013160335A2 (en) | 2012-04-26 | 2013-10-31 | Novartis Ag | Antigens and antigen combinations |
US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
HUE044612T2 (hu) | 2012-05-04 | 2019-11-28 | Pfizer | Prosztata-asszociált antigének és vakcina-alapú immunterápiás rendek |
MX2014014067A (es) | 2012-05-22 | 2015-02-04 | Novartis Ag | Conjugado de serogrupo x de meningococo. |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CA2882619A1 (en) | 2012-09-06 | 2014-03-13 | Novartis Ag | Combination vaccines with serogroup b meningococcus and d/t/p |
SG10201702685WA (en) | 2012-10-03 | 2017-04-27 | Glaxosmithkline Biolog Sa | Immunogenic composition |
MX2015004652A (es) | 2012-10-12 | 2015-08-05 | Glaxosmithkline Biolog Sa | Antigenos de pertusis acelulares no entrelazados para uso en vacunas de combinacion. |
US20140193451A1 (en) * | 2012-10-17 | 2014-07-10 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
KR20150058571A (ko) * | 2012-10-17 | 2015-05-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
TR201807340T4 (tr) | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. |
CA2911826C (en) | 2013-05-10 | 2022-08-23 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
CA2909586C (en) | 2013-05-15 | 2021-08-31 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
CN103386126B (zh) * | 2013-06-25 | 2015-06-17 | 北京科兴生物制品有限公司 | 一种含肠道病毒抗原的多价免疫原性组合物 |
CA2923129C (en) | 2013-09-08 | 2020-06-09 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
PL3096783T3 (pl) | 2014-01-21 | 2021-12-13 | Pfizer Inc. | Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
DK3096785T3 (da) | 2014-01-21 | 2020-09-21 | Pfizer | Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
LT3110442T (lt) | 2014-02-28 | 2020-12-28 | Glaxosmithkline Biologicals Sa | Modifikuoti meningokokinio fhbp polipeptidai |
EP2921856B1 (en) * | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
CN104829711B (zh) * | 2014-04-08 | 2018-04-03 | 北京天成新脉生物技术有限公司 | 脑膜炎球菌荚膜多糖单克隆抗体及其应用 |
MX2017001038A (es) | 2014-07-23 | 2018-02-09 | Childrens Hospital & Res Center At Oakland | Variantes de proteina de unión al factor h y metodos de uso de estas. |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
EP3034516A1 (en) | 2014-12-19 | 2016-06-22 | Novartis AG | Purification of streptococcal capsular polysaccharide |
ES2945312T3 (es) | 2015-01-15 | 2023-06-30 | Pfizer | Composiciones inmunogénicas para su uso en vacunas antineumocócicas |
CN104548090B (zh) * | 2015-01-27 | 2016-11-30 | 中国科学院过程工程研究所 | 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法 |
WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
EP3109255A1 (en) | 2015-06-26 | 2016-12-28 | Institut National De La Recherche Agronomique | Immunogenic composition |
WO2017005851A1 (en) | 2015-07-07 | 2017-01-12 | Affiris Ag | Vaccines for the treatment and prevention of ige mediated diseases |
PE20180657A1 (es) | 2015-07-21 | 2018-04-17 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
WO2017096374A1 (en) | 2015-12-04 | 2017-06-08 | Dana-Farber Cancer Institute, Inc. | Vaccination with mica/b alpha 3 domain for the treatment of cancer |
PL3405212T3 (pl) | 2016-01-19 | 2020-11-16 | Pfizer Inc. | Szczepionki przeciwnowotworowe |
US11612664B2 (en) | 2016-04-05 | 2023-03-28 | Gsk Vaccines S.R.L. | Immunogenic compositions |
EP3474890A1 (en) * | 2016-06-22 | 2019-05-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. | Pneumococcal polysaccharide-protein conjugate composition |
WO2018027126A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
WO2018027123A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
EP3506933A2 (en) | 2016-09-02 | 2019-07-10 | GlaxoSmithKline Biologicals SA | Vaccines for neisseria gonorrhoeae |
US11478537B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
CN117801069A (zh) | 2016-10-07 | 2024-04-02 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
EP3551668A1 (en) | 2016-12-06 | 2019-10-16 | GlaxoSmithKline Biologicals S.A. | Purification process for capsular polysaccharide |
DK3570879T3 (da) | 2017-01-20 | 2022-04-11 | Pfizer | Immunogene sammensætninger til anvendelse i pneumokokvacciner |
PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
CN110520154B (zh) * | 2017-03-15 | 2023-08-04 | 株式会社Lg化学 | 多价肺炎链球菌疫苗组合物 |
JP2020515587A (ja) | 2017-03-31 | 2020-05-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 免疫原性組成物、使用及び処置方法 |
WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
WO2018227177A1 (en) | 2017-06-10 | 2018-12-13 | Inventprise, Llc | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
MX2020001820A (es) | 2017-08-14 | 2020-03-20 | Glaxosmithkline Biologicals Sa | Metodos para reforzar las respuestas inmunitarias. |
CN111683678B (zh) | 2017-12-06 | 2024-01-26 | 默沙东有限责任公司 | 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法 |
SG11202006387QA (en) | 2018-02-05 | 2020-07-29 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
AU2019215216A1 (en) | 2018-02-05 | 2020-07-23 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
EP3773673A2 (en) | 2018-04-11 | 2021-02-17 | Enterome S.A. | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation |
ES2935702T3 (es) | 2018-04-11 | 2023-03-09 | Enterome S A | Péptidos antigénicos para la prevención y el tratamiento del cáncer |
CN111989114A (zh) | 2018-04-18 | 2020-11-24 | Sk生物科学株式会社 | 肺炎链球菌的荚膜多糖以及其免疫原性缀合物 |
CN112673054A (zh) | 2018-07-19 | 2021-04-16 | 葛兰素史密丝克莱恩生物有限公司 | 用于制备干燥多糖的方法 |
BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
US20220054632A1 (en) | 2018-12-12 | 2022-02-24 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
WO2020121159A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
JP7275277B2 (ja) | 2018-12-19 | 2023-05-17 | メルク・シャープ・アンド・ドーム・エルエルシー | ストレプトコッカス・ニューモニエ多糖-タンパク質コンジュゲートを含む組成物およびその使用方法 |
EP3923982A1 (en) | 2019-02-11 | 2021-12-22 | Pfizer Inc. | Neisseria meningitidiscompositions and methods thereof |
JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
EP3952906A1 (en) | 2019-04-10 | 2022-02-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
US20220221455A1 (en) | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
US20220211859A1 (en) | 2019-05-10 | 2022-07-07 | Glaxosmithkline Biologicals Sa | Conjugate production |
CN114667158A (zh) | 2019-08-05 | 2022-06-24 | 葛兰素史克生物有限公司 | 免疫原性组合物 |
CA3148928A1 (en) | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Process for preparing a composition comprising a protein d polypeptide |
MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
EP4045150A1 (en) | 2019-10-16 | 2022-08-24 | Enterome S.A. | Immunogenic compounds for treatment of adrenal cancer |
US20230000966A1 (en) | 2019-11-01 | 2023-01-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
LT4021487T (lt) | 2019-11-15 | 2024-02-12 | Enterome S.A. | Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui |
EP4061412A1 (en) | 2019-11-22 | 2022-09-28 | GlaxoSmithKline Biologicals S.A. | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
US20220409539A1 (en) * | 2019-12-30 | 2022-12-29 | Fraunhofer Usa Inc. | Particles for multi-dose delivery |
MX2022010355A (es) | 2020-02-21 | 2022-09-21 | Pfizer | Purificacion de sacaridos. |
WO2021165928A2 (en) | 2020-02-23 | 2021-08-26 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CN111588847B (zh) * | 2020-05-18 | 2023-05-26 | 广州中医药大学(广州中医药研究院) | 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用 |
WO2021250626A2 (en) | 2020-06-12 | 2021-12-16 | Glaxosmithkline Biologicals Sa | Dock tag system |
CA3191005A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
KR20230096033A (ko) | 2020-10-27 | 2023-06-29 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그의 방법 |
AU2021373358A1 (en) | 2020-11-04 | 2023-06-01 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
WO2022178196A1 (en) | 2021-02-19 | 2022-08-25 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
JP2024510717A (ja) | 2021-02-22 | 2024-03-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物、使用及び方法 |
EP4070814A1 (en) | 2021-04-07 | 2022-10-12 | Lama France | Sars-cov-2 polypeptides and uses thereof |
CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
BR112023023671A2 (pt) | 2021-05-28 | 2024-02-06 | Pfizer | Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos |
CA3237496A1 (en) | 2021-11-18 | 2023-05-25 | Matrivax, Inc. | Immunogenic fusion protein compositions and methods of use thereof |
AU2023207315A1 (en) | 2022-01-13 | 2024-06-27 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
KR20230116601A (ko) | 2022-01-28 | 2023-08-04 | 이동민 | 머신 좌표계와 영상 좌표계의 정합 방법 및 장치 |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
WO2023187127A1 (en) | 2022-03-31 | 2023-10-05 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
WO2024110839A2 (en) | 2022-11-22 | 2024-05-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
BE889979A (fr) | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
US5360897A (en) * | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
US4761283A (en) * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US4882317A (en) * | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
ATE205534T1 (de) * | 1988-12-16 | 2001-09-15 | Nederlanden Staat | Pneumolysin-mutanten und pneumokokken-impfstoffe daraus |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
NZ239643A (en) * | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
RU2118164C1 (ru) | 1992-06-25 | 1998-08-27 | Смитклайн Бичам Байолоджикалс, С.А. | Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины |
EP0618813B1 (en) * | 1992-09-16 | 2002-01-09 | The University Of Tennessee Research Corporation | Antigen of hybrid m protein and carrier for group a streptococcal vaccine |
DK0812593T4 (da) | 1993-03-23 | 2008-05-13 | Smithkline Beecham Biolog | Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A |
DE69431624T2 (de) | 1993-05-18 | 2003-07-10 | The Ohio State University Research Foundation, Columbus | Impfstoff gegen mittelohrentzündung |
DE122009000058I1 (de) | 1993-09-22 | 2009-12-31 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US5565204A (en) * | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
US5681570A (en) * | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
KR19990007858A (ko) * | 1995-04-17 | 1999-01-25 | 존 더블유.로우 | 박테리아의 리포프로테인으로 폴리사카라이드에 대한 면역반응의 유도및 강화 |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
WO1996040242A1 (en) | 1995-06-07 | 1996-12-19 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein |
US5736533A (en) * | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
EA199800046A1 (ru) | 1995-06-07 | 1998-06-25 | Байокем Вэксинс Инк. | Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
SE9601158D0 (sv) | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
US6245335B1 (en) * | 1996-05-01 | 2001-06-12 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
WO1997041151A2 (en) | 1996-05-01 | 1997-11-06 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
JPH102001A (ja) * | 1996-06-15 | 1998-01-06 | Okajima Kogyo Kk | グレーチング |
US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
CA2292838A1 (en) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Lactoferrin receptor genes of moraxella |
HUP0002475A3 (en) | 1997-07-21 | 2002-01-28 | Baxter Healthcare S A Wallisel | Modified immunogenic pneumolysin compositions as vaccines |
US6224880B1 (en) * | 1997-09-24 | 2001-05-01 | Merck & Co., Inc. | Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines |
US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
US6709658B1 (en) * | 1998-02-12 | 2004-03-23 | Wyeth Holdings Corporation | Pneumococcal vaccines formulated with interleukin-12 |
AU766455C (en) | 1998-04-07 | 2004-12-02 | Medimmune, Llc | Derivatives of pneumococcal choline binding proteins for vaccines |
GB9812613D0 (en) | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
DE69941574D1 (de) | 1998-08-19 | 2009-12-03 | Baxter Healthcare Sa | Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid |
DE69940439D1 (de) * | 1998-12-21 | 2009-04-02 | Medimmune Inc | Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
CN201252175Y (zh) * | 2008-08-04 | 2009-06-03 | 富士康(昆山)电脑接插件有限公司 | 线缆连接器组件 |
-
2000
- 2000-03-17 HU HU0200373A patent/HU228499B1/hu not_active IP Right Cessation
- 2000-03-17 IL IL14504400A patent/IL145044A0/xx active IP Right Grant
- 2000-03-17 CN CNB008077738A patent/CN100339130C/zh not_active Expired - Fee Related
- 2000-03-17 TW TW089104978A patent/TWI286938B/zh not_active IP Right Cessation
- 2000-03-17 AR ARP000101194A patent/AR022963A1/es not_active Application Discontinuation
- 2000-03-17 WO PCT/EP2000/002465 patent/WO2000056358A2/en not_active Application Discontinuation
- 2000-03-17 MY MYPI20001047A patent/MY125387A/en unknown
- 2000-03-17 ES ES00910868T patent/ES2339737T3/es not_active Expired - Lifetime
- 2000-03-17 JP JP2000606262A patent/JP2002539273A/ja active Pending
- 2000-03-17 IL IL14504300A patent/IL145043A0/xx active IP Right Grant
- 2000-03-17 BR BR0009166-9A patent/BR0009166A/pt not_active Application Discontinuation
- 2000-03-17 PL PL355180A patent/PL204890B1/pl unknown
- 2000-03-17 HU HU0200664A patent/HUP0200664A2/hu unknown
- 2000-03-17 BR BR0009154-5A patent/BR0009154A/pt not_active IP Right Cessation
- 2000-03-17 DE DE60032120T patent/DE60032120T2/de not_active Expired - Lifetime
- 2000-03-17 HU HU0200367A patent/HU229968B1/hu active Protection Beyond IP Right Term
- 2000-03-17 TR TR2001/02736T patent/TR200102736T2/tr unknown
- 2000-03-17 KR KR1020017011939A patent/KR100798212B1/ko not_active IP Right Cessation
- 2000-03-17 EP EP06124454A patent/EP1776962A1/en not_active Ceased
- 2000-03-17 PL PL355264A patent/PL203917B1/pl unknown
- 2000-03-17 CZ CZ20013379A patent/CZ301445B6/cs not_active IP Right Cessation
- 2000-03-17 IL IL14504500A patent/IL145045A0/xx unknown
- 2000-03-17 NZ NZ513840A patent/NZ513840A/xx not_active IP Right Cessation
- 2000-03-17 SI SI200030925T patent/SI1162999T1/sl unknown
- 2000-03-17 WO PCT/EP2000/002467 patent/WO2000056359A2/en active IP Right Grant
- 2000-03-17 AR ARP000101195A patent/AR022964A1/es unknown
- 2000-03-17 AU AU32919/00A patent/AU750788B2/en not_active Ceased
- 2000-03-17 DK DK00916983T patent/DK1162999T3/da active
- 2000-03-17 EP EP00910868A patent/EP1162998B1/en not_active Expired - Lifetime
- 2000-03-17 CZ CZ20013380A patent/CZ303653B6/cs not_active IP Right Cessation
- 2000-03-17 KR KR1020017011941A patent/KR100642044B1/ko not_active IP Right Cessation
- 2000-03-17 PT PT00912626T patent/PT1163000E/pt unknown
- 2000-03-17 CA CA002366152A patent/CA2366152A1/en not_active Abandoned
- 2000-03-17 EP EP07119247A patent/EP1880735A3/en not_active Withdrawn
- 2000-03-17 TW TW089104976A patent/TWI235064B/zh not_active IP Right Cessation
- 2000-03-17 CA CA2366314A patent/CA2366314C/en not_active Expired - Lifetime
- 2000-03-17 EP EP00912626A patent/EP1163000B1/en not_active Expired - Lifetime
- 2000-03-17 AT AT00912626T patent/ATE387214T1/de active
- 2000-03-17 ES ES00916983T patent/ES2275499T3/es not_active Expired - Lifetime
- 2000-03-17 KR KR1020017011948A patent/KR20020000785A/ko not_active Application Discontinuation
- 2000-03-17 AT AT00916983T patent/ATE346608T1/de active
- 2000-03-17 CZ CZ20013378A patent/CZ20013378A3/cs unknown
- 2000-03-17 PL PL00355178A patent/PL355178A1/xx not_active Application Discontinuation
- 2000-03-17 CN CNB008077592A patent/CN1191852C/zh not_active Expired - Fee Related
- 2000-03-17 AT AT00910868T patent/ATE459373T1/de not_active IP Right Cessation
- 2000-03-17 SI SI200030988T patent/SI1163000T1/sl unknown
- 2000-03-17 CA CA002365296A patent/CA2365296A1/en not_active Abandoned
- 2000-03-17 DK DK00912626T patent/DK1163000T3/da active
- 2000-03-17 JP JP2000606264A patent/JP4846906B2/ja not_active Expired - Lifetime
- 2000-03-17 BR BR0009163-4A patent/BR0009163A/pt not_active IP Right Cessation
- 2000-03-17 EP EP10180520A patent/EP2277535A3/en not_active Ceased
- 2000-03-17 DE DE60043930T patent/DE60043930D1/de not_active Expired - Lifetime
- 2000-03-17 AU AU38136/00A patent/AU750762B2/en not_active Ceased
- 2000-03-17 CN CNB00807528XA patent/CN1192798C/zh not_active Expired - Lifetime
- 2000-03-17 DE DE60038166T patent/DE60038166T2/de not_active Expired - Lifetime
- 2000-03-17 WO PCT/EP2000/002468 patent/WO2000056360A2/en active IP Right Grant
- 2000-03-17 BR BRPI0009163A patent/BRPI0009163B8/pt unknown
- 2000-03-17 MX MXPA01009452A patent/MXPA01009452A/es not_active Application Discontinuation
- 2000-03-17 TW TW089104977A patent/TWI281403B/zh not_active IP Right Cessation
- 2000-03-17 TR TR2001/02739T patent/TR200102739T2/tr unknown
- 2000-03-17 AU AU34307/00A patent/AU750913B2/en not_active Expired
- 2000-03-17 ES ES00912626T patent/ES2300255T3/es not_active Expired - Lifetime
- 2000-03-17 JP JP2000606263A patent/JP2002540074A/ja not_active Withdrawn
- 2000-03-17 MY MYPI20001077A patent/MY125202A/en unknown
- 2000-03-17 AR ARP000101196A patent/AR022965A1/es not_active Application Discontinuation
- 2000-03-17 EP EP00916983A patent/EP1162999B1/en not_active Expired - Lifetime
- 2000-03-17 NZ NZ513841A patent/NZ513841A/en not_active IP Right Cessation
- 2000-03-17 PT PT00916983T patent/PT1162999E/pt unknown
- 2000-03-17 DE DE122009000054C patent/DE122009000054I1/de active Pending
- 2000-03-17 TR TR2001/02735T patent/TR200102735T2/tr unknown
-
2001
- 2001-03-17 NZ NZ513842A patent/NZ513842A/en unknown
- 2001-08-22 IL IL145044A patent/IL145044A/en not_active IP Right Cessation
- 2001-08-22 IL IL145043A patent/IL145043A/en not_active IP Right Cessation
- 2001-09-05 NO NO20014323A patent/NO330532B1/no not_active IP Right Cessation
- 2001-09-05 NO NO20014325A patent/NO330736B1/no not_active IP Right Cessation
- 2001-09-05 NO NO20014322A patent/NO20014322L/no not_active Application Discontinuation
-
2002
- 2002-05-21 HK HK02103795.9A patent/HK1043728B/zh not_active IP Right Cessation
- 2002-05-21 HK HK02103814.6A patent/HK1043731B/zh not_active IP Right Cessation
- 2002-05-21 HK HK02103797.7A patent/HK1043730A1/zh unknown
- 2002-08-26 US US10/228,666 patent/US20030147922A1/en not_active Abandoned
-
2004
- 2004-08-27 US US10/929,042 patent/US20050031646A1/en active Pending
-
2005
- 2005-08-31 US US11/216,226 patent/US20060002961A1/en not_active Abandoned
- 2005-09-30 US US11/240,193 patent/US20060093626A1/en not_active Abandoned
-
2007
- 2007-02-21 CY CY20071100247T patent/CY1107561T1/el unknown
-
2008
- 2008-04-10 CY CY20081100394T patent/CY1107390T1/el unknown
-
2009
- 2009-09-24 BE BE2009C043C patent/BE1025464I2/fr unknown
- 2009-09-24 CY CY2009014C patent/CY2009014I2/el unknown
- 2009-09-24 NL NL300415C patent/NL300415I1/nl unknown
- 2009-11-05 US US12/612,988 patent/US8926985B2/en not_active Expired - Lifetime
-
2010
- 2010-02-11 LU LU91652C patent/LU91652I2/fr unknown
- 2010-02-16 FR FR10C0008C patent/FR10C0008I2/fr active Active
- 2010-06-03 US US12/793,408 patent/US20100291138A1/en not_active Abandoned
- 2010-12-21 US US12/973,899 patent/US20110217329A1/en not_active Abandoned
- 2010-12-24 JP JP2010288197A patent/JP5551579B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-30 NO NO2011014C patent/NO2011014I1/no unknown
-
2014
- 2014-11-21 US US14/550,345 patent/US9168313B2/en not_active Expired - Fee Related
-
2015
- 2015-07-14 HU HUS1500040C patent/HUS1500040I1/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200102736T2 (tr) | Aşı. | |
NZ505107A (en) | Vaccine comprising CpG oligonucleotide and Streptococcus pnueumoniae antigen | |
TR201900418T4 (tr) | Pnömokok polisakkarit konjugat aşısı. | |
CY1112280T1 (el) | Συνθεση πολυδυναμου εμβολιου | |
MXPA05009351A (es) | Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales. | |
PT1104306E (pt) | Composicoes de cpg e adjuvantes de saponina e seus metodos | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
ES2179261T3 (es) | Vacuna a base de streptococcus equi. | |
DE602005023422D1 (de) | Konjugats | |
BR0310042A (pt) | Vacinas de combinação mucosal para meningite bacteriana | |
PT1154790E (pt) | Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg | |
WO2002034773A3 (en) | Streptococcal genes | |
MX9707944A (es) | Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos. | |
ATE370745T1 (de) | Verbesserte polysaccharid- und glykokonjugat- vakzine | |
DE69936296D1 (de) | Konjugat-impfstoffe zur vorbeugung der zahnkaries | |
WO2005007804A3 (en) | Anthrax conjugate vaccine and antibodies | |
HK1035141A1 (en) | Methods and compositions for detection and diagnosis of infectious diseases. | |
WO2001040472A3 (en) | Streptococcus pneumoniae antigens | |
WO2002004497A3 (en) | Multiple antigenic peptides immunogenic against streptococcus pneumoniae | |
AU6761301A (en) | Adjuvant composition comprising fha protein or fragment of fha protein in free form | |
BR9905780A (pt) | Antìgenos vacinais de leptospira para prevenção da laptospirose | |
SE9600646D0 (sv) | Vaccin | |
WO2001073037A3 (en) | R5 protein, a cell-surface protective antigen of group b streptococci | |
SE9602149D0 (sv) | Conjugate vaccine against streptococcus pneumoniae |